Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | A2B530 |
Synonyms | |
Therapy Description |
A2B530 are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CEACAM5 (CEA), an LIR-1-based inhibitory receptor targeting HLA-A*02, and an shRNA targeting beta2 microglobulin, which potentially induce tumor cell killing and inhibition of tumor growth (Journal for ImmunoTherapy of Cancer 2022;10). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
A2B530 | A-2B530|A 2B530|CEA Tmod | A2B530 are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CEACAM5 (CEA), an LIR-1-based inhibitory receptor targeting HLA-A*02, and an shRNA targeting beta2 microglobulin, which potentially induce tumor cell killing and inhibition of tumor growth (Journal for ImmunoTherapy of Cancer 2022;10). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05736731 | Phase Ib/II | A2B530 | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression (EVEREST-1) | Recruiting | USA | 0 |